Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
复制标题

DOI:
10.1080/14760584.2017.1371594
复制
发表时间:
2017-10
影响因子:
6.2
通讯作者:
Amara RR
Amara RR
中科院分区:
医学2区
文献类型:
--
作者:
Chea LS;Amara RR

文献摘要

参考文献

被引文献

相似文献

尽管对艾滋病毒进行了30年的研究,但预防感染和限制疾病进展的疫苗仍然难以找到。RV144试验在人类中显示了中等但显著的保护作用,并强调了针对HIV包膜的抗体反应作为保护的重要免疫相关性的贡献。进一步推进这一进展的努力包括使用异种Prime-Boost方案,使用DNA作为引发剂,并使用减毒牛痘病毒--改良安卡拉痘苗病毒(MVA)作为增强载体,以产生保护性的艾滋病毒特异性免疫。在这篇综述中,我们总结了DNA/MVA疫苗在非人类灵长类动物模型中的免疫原性,并描述了在SIV感染模型中所看到的效果。我们讨论了由这些研究确定的保护性的免疫学相关性,以及提高保护性免疫的潜在方法。此外,我们还介绍了DNA/MVA疫苗在人体试验中的最新进展。过去十年的努力为更好地了解疫苗诱导的免疫反应的动态以及预防艾滋病毒的免疫相关性提供了机会。根据我们所了解的,我们概述了该领域在未来五年可能重点关注的多个领域。
Despite 30 years of research on HIV, a vaccine to prevent infection and limit disease progression remains elusive. The RV144 trial showed moderate, but significant protection in humans and highlighted the contribution of antibody responses directed against HIV envelope as an important immune correlate for protection. Efforts to further build upon the progress include the use of a heterologous prime-boost regimen using DNA as the priming agent and the attenuated vaccinia virus, Modified Vaccinia Ankara (MVA), as a boosting vector for generating protective HIV-specific immunity. In this review, we summarize the immunogenicity of DNA/MVA vaccines in non-human primate models and describe the efficacy seen in SIV infection models. We discuss immunological correlates of protection determined by these studies and potential approaches for improving the protective immunity. Additionally, we describe the current progress of DNA/MVA vaccines in human trials. Efforts over the past decade have provided the opportunity to better understand the dynamics of vaccine-induced immune responses and immune correlates of protection against HIV. Based on what we have learned, we outline multiple areas where the field will likely focus on in the next five years.
DOI: 10.1016/j.vaccine.2011.12.131
发表时间: 2012-02-27
期刊: VACCINE
影响因子: 5.5
作者:
Cox, Josephine H.;Ferrari, Maria G.;Earl, Patricia;Lane, James R.;Jagodzinski, Linda L.;Polonis, Victoria R.;Kuta, Ellen G.;Boyer, Jean D.;Ratto-Kim, Silvia;Eller, Leigh-Anne;Doan-Trang Pham;Hart, Lydia;Montefiori, David;Ferrari, Guido;Parrish, Stephanie;Weiner, David B.;Moss, Bernard;Kim, Jerome H.;Birx, Deborah;VanCott, Thomas C.
通讯作者: VanCott, Thomas C.
DOI: 10.1128/cvi.00008-10
发表时间: 2010-07-01
影响因子: --
作者:
Aboud, Said;Nilsson, Charlotta;Godoy-Ramirez, Karina
通讯作者: Godoy-Ramirez, Karina
DOI: 10.1016/j.virusres.2005.08.008
发表时间: 2006-03-01
期刊: VIRUS RESEARCH
影响因子: 5
作者:
Abaitua, F;Rodríguez, JR;Esteban, M
通讯作者: Esteban, M
DOI: 10.1016/j.vaccine.2013.03.021
发表时间: 2013-09-06
期刊: VACCINE
影响因子: 5.5
作者:
Cottingham, Matthew G.;Carroll, Miles W.
通讯作者: Carroll, Miles W.
DOI: 10.1093/ofid/ofw034
发表时间: 2016-01
影响因子: 4.2
作者:
Chamcha V;Kannanganat S;Gangadhara S;Nabi R;Kozlowski PA;Montefiori DC;LaBranche CC;Wrammert J;Keele BF;Balachandran H;Sahu S;Lifton M;Santra S;Basu R;Moss B;Robinson HL;Amara RR
通讯作者: Amara RR